InflaRx shares surge 28.46% after-hours on positive Phase 2a INF904 data for HS and CSU.

InflaRx surged 28.46% in after-hours trading following the release of positive Phase 2a clinical trial data for its oral C5aR inhibitor INF904 in treating hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The trial demonstrated rapid and meaningful reductions in inflammatory lesions, pain, and urticaria activity scores, with no serious adverse events reported. InflaRx highlighted INF904’s potential as a “pipeline-in-a-product” with biologic-like efficacy and plans to advance to Phase 2b trials in HS by 2026. The data, coupled with plans for a webcast and capital markets event, reinforced investor optimism about INF904’s development pipeline and market potential exceeding $1 billion. The after-hours rally aligns with the company’s emphasis on INF904’s safety profile, robust efficacy signals, and strategic collaborations to accelerate development.